Rein Therapeutics (RNTX) Non-Current Debt (2018)

Rein Therapeutics (RNTX) posted quarterly Non-Current Debt of $5.3 million for Q4 2018, up 6.9% quarter-over-quarter from $5.0 million in Q3 2018.

Rein Therapeutics (RNTX) Non-Current Debt (2018) Analysis & Trends

Rein Therapeutics (RNTX) has reported Non-Current Debt for 1 consecutive years, with $5.3 million the latest figure, recorded in Q4 2018.

In Q4 2018, Non-Current Debt changed N/A year-over-year to $5.3 million; the TTM figure through Dec 2018 stood at $5.3 million (changed N/A YoY), while the FY2018 annual figure was $5.3 million, changed N/A from the prior year.
Non-Current Debt advanced to $5.3 million in Q4 2018 per RNTX's latest filing, from $5.0 million in the prior quarter.
Across five years, Non-Current Debt topped out at $5.3 million in Q4 2018 and bottomed at $3.3 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Rein Therapeutics	55.49 Mn	55.49 Mn	-	-

Download Data